Literature DB >> 20015980

Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency.

Chih-Ping Mao1, Chien-Fu Hung, Tae Heung Kang, Liangmei He, Ya-Chea Tsai, Chao-Yi Wu, T-C Wu.   

Abstract

DNA vaccines have recently emerged at the forefront of approaches to harness the immune system in the prevention and treatment of viral infections, as well as the prevention and treatment of cancers. However, these vaccines suffer from limited efficacy since they often fail to produce significant antigen-specific CD8(+) T-cell responses. We report here a novel concept for DNA vaccine design that exploits the unique and powerful ability of viral fusogenic membrane glycoproteins (FMGs) to couple concentrated antigen transfer to dendritic cells (DCs) with local induction of the acute inflammatory response. Intramuscular administration into mice by electroporation technology of a plasmid containing the FMG gene from vesicular stomatitis virus (VSV-G)-together with DNA encoding the E7 protein of human papillomavirus type 16, a model cervical cancer antigen-elicited robust E7-specific CD8(+) T-cell responses, as well as therapeutic control of E7-expressing tumors. This effect could potentially be mediated through the immunogenic form of cellular fusion and necrosis induced by VSV-G, which in a concerted fashion provokes leukocyte infiltration into the inoculation site, enhances cross-presentation of antigen to DCs, and stimulates them to mature efficiently. Thus, the incorporation of FMGs into DNA vaccines holds promise for the successful control of viral infections and cancers in the clinic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015980      PMCID: PMC2820938          DOI: 10.1128/JVI.01954-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene.

Authors:  C H Chen; T L Wang; C F Hung; Y Yang; R A Young; D M Pardoll; T C Wu
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

2.  Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.

Authors:  A Bateman; F Bullough; S Murphy; L Emiliusen; D Lavillette; F L Cosset; R Cattaneo; S J Russell; R G Vile
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

3.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Cooperation between CD4+ and CD8+ T cells: when, where, and how.

Authors:  Flora Castellino; Ronald N Germain
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

5.  Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

Authors:  T M Fu; J B Ulmer; M J Caulfield; R R Deck; A Friedman; S Wang; X Liu; J J Donnelly; M A Liu
Journal:  Mol Med       Date:  1997-06       Impact factor: 6.354

6.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

Authors:  Z Shen; G Reznikoff; G Dranoff; K L Rock
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

7.  Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.

Authors:  J Wolfers; A Lozier; G Raposo; A Regnault; C Théry; C Masurier; C Flament; S Pouzieux; F Faure; T Tursz; E Angevin; S Amigorena; L Zitvogel
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

8.  Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits.

Authors:  Janet L Brandsma; Mark Shlyankevich; Linda Buonocore; Anjeanette Roberts; Steven M Becker; John K Rose
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

9.  SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques.

Authors:  Jean D Boyer; Tara M Robinson; Michele A Kutzler; R Parkinson; Sandra A Calarota; Maninder K Sidhu; Karuppiah Muthumani; Mark Lewis; George Pavlakis; Barbara Felber; David Weiner
Journal:  J Med Primatol       Date:  2005-10       Impact factor: 0.667

10.  Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.

Authors:  B Sauter; M L Albert; L Francisco; M Larsson; S Somersan; N Bhardwaj
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  5 in total

1.  A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.

Authors:  Jason Gummow; Yanrui Li; Wenbo Yu; Tamsin Garrod; Danushka Wijesundara; Amelia J Brennan; Ranajoy Mullick; Ilia Voskoboinik; Branka Grubor-Bauk; Eric J Gowans
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

2.  Systemic delivery of fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells.

Authors:  Detu Zhu; Dang Hoang Lam; Yovita Ida Purwanti; Sal Lee Goh; Chunxiao Wu; Jieming Zeng; Weimin Fan; Shu Wang
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

3.  Vaccine potential of Nipah virus-like particles.

Authors:  Pramila Walpita; Jennifer Barr; Michael Sherman; Christopher F Basler; Linfa Wang
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

Review 4.  Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines.

Authors:  Ashish C Shrestha; Danushka K Wijesundara; Makutiro G Masavuli; Zelalem A Mekonnen; Eric J Gowans; Branka Grubor-Bauk
Journal:  Vaccines (Basel)       Date:  2019-04-30

5.  New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.

Authors:  Alessandra Lopes; Chiara Bastiancich; Mathilde Bausart; Sophie Ligot; Laure Lambricht; Kevin Vanvarenberg; Bernard Ucakar; Bernard Gallez; Véronique Préat; Gaëlle Vandermeulen
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.